Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial

Siow Ming Lee, Penella J Woll, Robin Rudd, David Ferry, Mary O'Brien, Gary Middleton, Stephen Spiro, Lindsay James, Kulsam Ali, Mark Jitlal, Allan Hackshaw

Research output: Contribution to journalArticlepeer-review

105 Citations (Scopus)

Abstract

Cancer cells rely on angiogenesis for growth and dissemination, and small cell lung cancer (SCLC) is a highly angiogenic tumor. We evaluated thalidomide, an anti-angiogenic agent, when combined with chemotherapy and as maintenance treatment.
Original languageEnglish
Pages (from-to)1049-57
Number of pages9
JournalJournal of the National Cancer Institute
Volume101
Issue number15
DOIs
Publication statusPublished - 2009

Fingerprint

Dive into the research topics of 'Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this